Literature DB >> 18510680

Risk factors for early death in neonates with Down syndrome and transient leukaemia.

Hideki Muramatsu1, Koji Kato, Nobuhiro Watanabe, Kimikazu Matsumoto, Tomohiko Nakamura, Yasuo Horikoshi, Junichi Mimaya, Chizuko Suzuki, Masahiro Hayakawa, Seiji Kojima.   

Abstract

Transient leukaemia (TL) in neonates with Down syndrome (DS) is characterized by the transient appearance of blast cells in the peripheral blood that resolves spontaneously. Some TL patients die at an early age due to organ failure. Seventy DS patients with TL were studied retrospectively to identify clinical and laboratory characteristics associated with early death (<6 months of age). Sixteen of 70 patients (22.9%) died early. The main causes of death were organ failure, particularly hepatic and cardiopulmonary failure. On univariate analysis, early gestational age (EGA), high white blood cell (WBC) count (> or =100 x 10(9)/l), percentage of peripheral blasts, elevated aspartate transaminase (AST), elevated direct bilirubin (DB), and low Apgar score were significantly associated with poor survival. On multivariate analysis, EGA, WBC count, and DB were independent predictors of poor outcome. A simple risk stratification system combining EGA and WBC count was devised to predict poor outcome. Term infants (EGA > or = 37 weeks) whose WBC count was lower than 100 x 10(9)/l had the best outcome [7.7% (3/39) died early], while preterm infants (EGA < 37 weeks) whose WBC count was higher than 100 x 10(9)/l had the worst outcome [54.5% (6/11) died early]. This stratification system may be useful for identifying high-risk patients who need early therapeutic interventions.

Entities:  

Mesh:

Year:  2008        PMID: 18510680     DOI: 10.1111/j.1365-2141.2008.07231.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

1.  Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study.

Authors:  Marius Flasinski; Kira Scheibke; Martin Zimmermann; Ursula Creutzig; Katarina Reinhardt; Femke Verwer; Valerie de Haas; Vincent H J van der Velden; Christine von Neuhoff; C Michel Zwaan; Dirk Reinhardt; Jan-Henning Klusmann
Journal:  Blood Adv       Date:  2018-07-10

2.  Transient leukemia in down syndrome: report of two cases with review of literature.

Authors:  Alka V Gosavi; Prashant S Murarkar; Dhaneshwar N Lanjewar; Ravishankar V Ravikar
Journal:  Indian J Hematol Blood Transfus       Date:  2011-06-21       Impact factor: 0.900

3.  Myeloid Proliferations Associated with Down Syndrome.

Authors:  Alan B Cantor
Journal:  J Hematop       Date:  2014-12-14       Impact factor: 0.196

4.  Liver disease is frequently observed in Down syndrome patients with transient abnormal myelopoiesis.

Authors:  Myoung Ja Park; Manabu Sotomatsu; Kentaro Ohki; Kokoro Arai; Kenichi Maruyama; Tomio Kobayashi; Akira Nishi; Kiyoko Sameshima; Takeshi Takagi; Yasuhide Hayashi
Journal:  Int J Hematol       Date:  2013-12-14       Impact factor: 2.490

5.  The landscape of somatic mutations in Down syndrome-related myeloid disorders.

Authors:  Kenichi Yoshida; Tsutomu Toki; Yusuke Okuno; Rika Kanezaki; Yuichi Shiraishi; Aiko Sato-Otsubo; Masashi Sanada; Myoung-ja Park; Kiminori Terui; Hiromichi Suzuki; Ayana Kon; Yasunobu Nagata; Yusuke Sato; RuNan Wang; Norio Shiba; Kenichi Chiba; Hiroko Tanaka; Asahito Hama; Hideki Muramatsu; Daisuke Hasegawa; Kazuhiro Nakamura; Hirokazu Kanegane; Keiko Tsukamoto; Souichi Adachi; Kiyoshi Kawakami; Koji Kato; Ryosei Nishimura; Shai Izraeli; Yasuhide Hayashi; Satoru Miyano; Seiji Kojima; Etsuro Ito; Seishi Ogawa
Journal:  Nat Genet       Date:  2013-09-22       Impact factor: 38.330

Review 6.  Hematological disorders and leukemia in children with Down syndrome.

Authors:  Annelyse Bruwier; Christophe F Chantrain
Journal:  Eur J Pediatr       Date:  2011-11-24       Impact factor: 3.183

Review 7.  Myeloid leukemia in Down syndrome.

Authors:  Irum Khan; Sébastien Malinge; John Crispino
Journal:  Crit Rev Oncog       Date:  2011

Review 8.  Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.

Authors:  Ana C Xavier; Yubin Ge; Jeffrey W Taub
Journal:  J Mol Diagn       Date:  2009-09       Impact factor: 5.568

Review 9.  Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome.

Authors:  Sébastien Malinge; Shai Izraeli; John D Crispino
Journal:  Blood       Date:  2009-01-12       Impact factor: 22.113

Review 10.  The prenatal origins of cancer.

Authors:  Glenn M Marshall; Daniel R Carter; Belamy B Cheung; Tao Liu; Marion K Mateos; Justin G Meyerowitz; William A Weiss
Journal:  Nat Rev Cancer       Date:  2014-03-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.